21 |
The role of the perinexus in Long QT Syndrome Type 3Wu, Xiaobo 13 February 2023 (has links)
Gain of function of cardiac voltage-gated sodium channel (Nav1.5) leads to Long QT Syndrome Type 3 (LQT3). LQT3 phenotype can be exacerbated by expanding the perinexus, which is an intercellular nanodomain with high density of Nav1.5 in the intercalated disc. Following this finding, we found that elevating extracellular sodium and widening the perinexus synergistically exacerbated LQT3 phenotype, Importantly, we also found that perinexal expansion increases the susceptibility to cardiac arrest in aged LQT3, which demonstrated that perinexal expansion is an arrhythmogenic risk especially in aged LQT3 patients. Furthermore, we observed that the perinexus narrows with aging and conceals LQT3 phenotype, which suggests that perinexal narrowing may have a cardio-protective role during aging in LQT3. Surprisingly, following the finding of the synergistic effect of extracellular sodium elevation and perinexal widening on LQT3 phenotype in drug-induced LQT3 guinea pig hearts, we found that this synergistic effect was not observed in genetically-modified LQT3 mouse hearts, which is due to high sodium also increasing transient outward potassium current (Ito). In summary, the whole project investigated the role of the perinexus in LQT3 from different conditions including sodium, aging and species. The findings in this project discovered the importance of perinexal expansion in LQT3 and also the involvement of Ito in sodium regulating LQT3 phenotype in hearts which functionally express Ito channels. Therefore, a LQT3 animal model which has similar electrophysiology close to human may be a great option for translational purpose. / Doctor of Philosophy / Long QT Syndrome Type 3 (LQT3) is an inherited heart disease with the phenotype of long QT interval in ECG. It has been found that LQT3 phenotype gets worse when a very tiny space in the heart, termed as the perinexus, is wide due to cardiac edema. Following this finding, we also found that increasing sodium concentration together with wide perinexus can further exacerbate LQT3 phenotype in guinea pig hearts. Furthermore, we found that widening the perinexus in aged LQT3 hearts causes cardiac death but not in adult, which suggests that perinexal widening worsens LQT3 phenotype and even leads to cardiac death in aged hearts. Besides, we found that the perinexus narrows with aging and there is no difference in LQT3 phenotype between adult and aged hearts, which suggests that the narrow perinexus during aging may protect the hearts from cardiac death in LQT3. Surprisingly, we discovered that increasing sodium and widening the perinexus together fails to exacerbate LQT3 phenotype when compared with widening the perinexus alone in LQT3 mouse hearts, which is due to high sodium increasing transient outward potassium current (Ito). Notably, Ito channels are not functionally expressed in guinea pig hearts. In summary, the whole project investigated the role of the perinexus in LQT3 from different conditions including sodium, aging and species. The findings in this project discovered the importance of perinexal expansion in LQT3 and also the involvement of Ito in sodium regulating LQT3 phenotype in hearts. Therefore, a LQT3 animal model which has similar electrophysiology close to human may be a great option for translational purpose.
|
22 |
Molecular and functional characterisation of Long QT Syndrome causing genesHedley, Paula Louise 04 1900 (has links)
Thesis (PhD)-- Stellenbosch University, 2014. / ENGLISH ABSTRACT: Ventricular arrhythmias are the most important cause of sudden cardiac death (SCD) among adults living in industrialised nations. Genetic factors have substantial effects in determining population-based risk for SCD and may also account for inter-individual variability in susceptibility. Great progress has been made in identifying genes underlying various Mendelian disorders associated with inherited arrhythmia susceptibility. The most well studied familial arrhythmia syndrome is the congenital long QT syndrome (LQTS) caused by mutations in genes encoding subunits of myocardial ion channels. Not all mutation carriers have equal risk for experiencing the clinical manifestations of disease (i.e. syncope, sudden death). This observation has raised the possibility that additional genetic factors may modify the risk of LQTS manifestations.
This study establishes the genetic aetiology of LQTS in South Africa and Denmark through the identification and characterisation of LQTS-causative mutations in five previously identified genes, as well as examining possible novel genetic causes of LQTS in a cohort comprising Danish and British probands. We have functionally characterised several of the mutations identified in this study and examined other cardiac phenotypes that may be explained by variants causing repolarisation disorders. / AFRIKAANSE OPSOMMING: Ventrikulêre aritmie bly die enkele belangrikste oorsaak van skielike hart dood (SCD) onder volwassenes wat in geïndustrialiseerde lande woon. Genetiese faktore het aansienlike gevolge in die bepaling van bevolking-gebaseerde risiko vir SCD en kan ook verantwoordelik wees vir die inter-individuele variasie in vatbaarheid. Groot vordering is gemaak in die identifisering van gene onderliggende verskeie Mendeliese siektes wat verband hou met geërf aritmie vatbaarheid. Die mees goed bestudeerde familie aritmie sindroom is die aangebore lang QT-sindroom (LQTS) wat veroorsaak word deur mutasies in gene kode subeenhede van miokardiale ioonkanale. Nie alle mutasie draers het 'n gelyke risiko vir die ervaring van die kliniese manifestasies van die siekte (dws sinkopee, skielike dood). Hierdie waarneming het die moontlikheid genoem dat genetiese faktore anders as die primêre siekte-verwante mutasie kan die risiko van LQTS manifestasies verander.
Hierdie studie stel die genetiese oorsake van LQTS in Suid-Afrika en Denemarke deur die identifisering en karakterisering van LQTS-veroorsakende mutasies in vyf voorheen geïdentifiseer gene, asook die behandeling van moontlike nuwe genetiese oorsake van LQTS in 'n groep wat bestaan uit van die Deense en die Britse probands. Ons het funksioneel gekenmerk verskeie van die mutasies wat in hierdie studie ondersoek en ander kardiovaskulêre fenotipes wat deur variante veroorsaak repolarisasie versteurings verduidelik word. / South African National Research Foundation / Harry and Doris Crossley Foundation / Danish Strategic Research Foundation.
|
23 |
Identification of the modulators of cardiac ion channel functionCarstens, Johanna J. 03 1900 (has links)
Thesis (MScMedSc (Biomedical Sciences. Molecular Biology and Human Genetics))--University of Stellenbosch, 2009. / The human ether-à-go-go-related gene (HERG) encodes the protein underlying the
cardiac potassium current IKr. Mutations in HERG may produce defective channels and
cause Long QT Syndrome (LQTS), a cardiac disease affecting 1 in 2500 people. The
disease is characterised by a prolonged QT interval on a surface electrocardiogram and
has a symptomatic variability of sudden cardiac death in childhood to asymptomatic
longevity. We hypothesised that genetic variation in the proteins that interact with HERG
might modify the clinical expression of LQTS. Yeast two-hybrid methodology was used
to screen a human cardiac cDNA library in order to identify putative HERG N-terminus
ligands. Successive selection stages reduced the number of putative HERG ligandcontaining
colonies (preys) from 268 to 8. Putative prey ligands were sequenced and
identified by BLAST-search. False positive ligands were excluded based on their
function and subcellular location. Three strong candidate ligands were identified: Rhoassociated
coiled-coil containing kinase 1 (ROCK1), γ-sarcoglycan (SGCG) and
microtubule-associated protein 1A (MAP1A). In vitro co-immunoprecipitation (Co-IP)
and mammalian two-hybrid (M2H) analyses were used to validate these proposed
interactions, but failed to do so. This should be further investigated. Analysis of
confirmed interactions will shed light on their functional role and might contribute to
understanding the symptomatic variability seen in LQTS.
|
24 |
Hodnocení dynamiky tepové frekvence a QTc intervalu v zotavení v závislosti na poloze těla / The Assessment of Heart Rate Dynamics and of the QTc Interval During Recovery Phase Depending on the Position of the BodyMecová, Marie January 2020 (has links)
At present, doctors are not consistent in the way they set the QTc interval in the recovery phase. The main goal of this study was to screen healthy subjects in the two different exercise stress tests and to compare the obtained data from both tests. We wanted to explore whether the heart rate and the QTc interval differs from each other when performed in two different body positions during the recovery phase. The main purpose was to present evidence that would prove or disprove a hypothesis that the figures differ in the different body positions. In the theoretical part we submitted the main information about the heart rate, the QT interval and the relationship between them. We compared the behaviour of the obtained data during the exercise and during the recovery phase. We described the causes of the QTc prolongation and how it is related to the cardiac arrhythmias. In the practical part we examined 20 healthy subjects. Each of them underwent two exercise stress tests on the bicycle ergometer, up to the subjective maximum level of the exercise intensity. The subjects then recovered in two different positions. The first one was a supine position. The second rest position was on the bicycle ergometer set to very low intensity. We found out that the 4-minute recovery phase, the most important for...
|
25 |
The impact of Congenital Long QT Syndrome on First Nations children and youth in Northern British ColumbiaBene Watts, Simona 23 August 2020 (has links)
Background: Long QT syndrome (LQTS) is a cardiac condition which predisposes individuals to syncope, seizures, and sudden cardiac death. There is a high prevalence of congenital LQTS in a First Nations community in Northern British Columbia due to the founder variant p.V205M in the KCNQ1 gene. Additionally, two other variants of interest are present in this population: the KCNQ1 p.L353L variant, previously noted to modify the phenotype of LQTS in adults, and the CPT1A p.P479L variant, a metabolic variant common in Northern Indigenous populations associated with hypoglycemia and sudden unexpected infant death.
Methods: We performed a mixed methods study to better understand the impact of LQTS in children and youth in this First Nations community. To learn about the clinical impact of LQTS, and better understand the effects of the KCNQ1 and CPT1A variants in children, we used statistical analysis to compare the cardiac phenotypes of 211 First Nations children with and without the p.V205M, p.L353L and p.P479L variants, alone and in combination. Ordinary Least Squares linear regression was used to compare the highest peak corrected QT interval (QTc). The peak QTc is an electrocardiogram measurement used in risk stratification of LQTS patients. Logistic regression was used to compare the rates of syncope and seizures experienced in childhood.
Additionally, to learn about the lived-experience of LQTS, we interviewed one young First Nations adult about her experiences growing up with LQTS as a teenager. From this interview, we conducted a qualitative case study analysis using Interpretative Phenomenological Analysis. All research was done in partnership with the First Nations community using community-based participatory methods.
Results: We found that the p.V205M variant conferred a 22.4ms increase in peak QTc (p<0.001). No other variants or variant interaction effects were observed to have a significant impact on peak QTc. No association between the p.V205M variant and loss of consciousness (LOC) events (syncope and seizures) was observed (OR(95%CI)=1.3(0.6-2.8); p=0.531). However, children homozygous for p.P479L were found to experience 3.3 times more LOC events compared to non-carriers (OR=3.3(1.3-8.3); p=0.011). With regard to the qualitative portion of the thesis, four superordinate (main) themes emerged from the case study: Daily life with Long QT Syndrome, Interactions with Medical Professionals, Finding Reassurance, and The In-Between Age. We found that even though our participant was asymptomatic and felt that she was not impacted by LQTS in her daily life, she considered certain elements of the condition to be stressful, such as taking a daily beta-blocker.
Conclusion: These results suggest that while the KCNQ1 p.V205M variant is observed to significantly prolong the peak QTc, the CPT1A p.P479L variant is more strongly associated with LOC events in children from this community. More research is needed to further determine the effect of these variants; however, our preliminary findings suggest management strategies, such as whether beta-blockers are indicated for p.V205M carriers, may need to be reassessed. The importance of developing a holistic, well-balanced approach to medical care, taking into consideration the personal perspectives and unique medical circumstances of each child is exemplified in this study. / Graduate
|
26 |
Investigating the Structural Dynamics and Topology of Human KCNQ1 Potassium Ion Channel using Solid-State NMR and EPR SpectroscopyDixit, Gunjan 17 July 2019 (has links)
No description available.
|
27 |
CFTR Potentiator PG-01 and Corrector KM-11060 can rescue hERG mutations traffickingZhang, J., Shang, Lijun, Ma, A. January 2016 (has links)
Yes / Type II congenitalLong QT syndrome (LQT2) is due to genetic mutations in hERG channel. Genetic or
pharmacological factors could potentially affect hERG channel biogenesis and contributes to LQTS, for example,
disease mutations G601S and T473P result in hERG trafficking deficiency [1,2]. Various rescue strategies for hERG
dysfuction are being developed. Some correctors for CFTR channel have been reported to act indirectly on
proteostasis pathways to promote folding and correction on hERG trafficking deficiency [3]. In this study, we tested the
hypothesis that the CFTR corrector KM-11060 and the potentiator PG-01 may correct hERG mutation trafficking
diseases.
We use HEK293 cell line expressing a well-studied trafficking disease mutation G601S-hERG channel [4]. We treated
cells with CFTR potentiator PG-01and corrector KM-11060, which function through different cellular mechanisms, and
assessed whether correction occurred via immunoblotting. Whole cell proteins from HEK 293 cells expressing hERG
channels were used for analysis [5]. Proteins were separated on 8% SDS-polyacrylamide electrophoresis gels for 1
hour, transferred onto PVDF membrane, and blocked for 1 h with 5% nonfat milk. The blots were incubated with the
primary antibody (Santa Cruz Biotechnology) for 12-16 h at 4C temperature and then incubated with a donkey antigoat
horseradish peroxidase-conjugated secondary antibody( Santa Cruz Biotechnology). Actin expression was used
for loading controls. The blots were visualized using the ECL detection kit (Genshare).Results were deemed
significantly different from controls by a one-way ANOVA (p < 0.05).
Our results show that both KM-11060 (5, 10, 20uM) and PG-01(5, 15 uM) can correct G601S mutant alleles of hERG
protein trafficking (Fig 1, 2). KM-11060 (20uM) but not PG-01(15 uM) enhance protein expression of wild type hERG
channel (Fig 2). Further treatment on cells at low temperature with different drug concentration will be tested.
Functional studies are also needed to test whether the drugs can correct the function of hERG mutation channel.
These results could potentially provide novel insight into the correction mechanism of CFTR potentiator and also help
to develop new treatment for LQT2.
|
28 |
Mechanistic Basis for Atrial and Ventricular Arrhythmias Caused by KCNQ1 MutationsBartos, Daniel C. 01 January 2013 (has links)
Cardiac arrhythmias are caused by a disruption of the normal initiation or propagation of electrical impulses in the heart. Hundreds of mutations in genes encoding ion channels or ion channel regulatory proteins are linked to congenital arrhythmia syndromes that increase the risk for sudden cardiac death. This dissertation focuses on how mutations in a gene (KCNQ1) that encodes a voltage-gated K+ ion channel (Kv7.1) can disrupt proper channel function and lead to abnormal repolarization of atrial and ventricular cardiomyocytes.
In the heart, Kv7.1 coassembles with a regulatory protein to conduct the slowly activating delayed rectifier K+ current (IKs). Loss-of-function KCNQ1 mutations are linked to type 1 long QT syndrome (LQT1), and typically decrease IKs, which can lead to ventricular action potential (AP) prolongation. In patients, LQT1 is often characterized by an abnormally long corrected QT (QTc) interval on an electrocardiogram (ECG), and increases the risk for polymorphic ventricular tachycardias.
KCNQ1 mutations are also linked to atrial fibrillation (AF), but cause a gain-of-function phenotype that increases IKs. Surprisingly, patients diagnosed with both LQT1 and AF are increasingly identified as genotype positive for a KCNQ1 mutation. The first aim of this dissertation was to determine a unique functional phenotype of KCNQ1 mutations linked to both arrhythmia syndromes by functional analyses via the whole-cell patch clamp technique in HEK293 cells.
A proportion of patients with LQT1-linked KCNQ1 mutations do not have abnormal QTc prolongation known as latent LQT1. Interestingly, exercise can reveal abnormal QTc prolongation in these patients. During exercise, beta-adrenergic activation stimulates PKA to phosphorylate Kv7.1, causing an increase in IKs to prevent ventricular AP prolongation. Therefore, the second aim of this dissertation was to determine a molecular mechanism of latent LQT1 through functional analyses in HEK293 cells while incorporating pharmacological and phosphomimetic approaches to study PKA regulation of mutant Kv7.1 channels.
The findings in this dissertation provide new insight into how KCNQ1 mutations disrupt the function of Kv7.1 in a basal condition or during beta-adrenergic activation. Also, this dissertation suggests these approaches will improve patient management by identifying mutation specific risk factors for patients with KCNQ1 mutations.
|
29 |
Athletes' heart and exercise related sudden cardiac death : across the age spanWilson, Mathew January 2010 (has links)
Background - Regular exercise reduces the risk of cardiovascular disease and subsequent sudden cardiac death (SCD). However, a small, but notable proportion of athletes die suddenly due to inherited or congenital disorders of the heart that predispose to malignant ventricular arrhythmias. Such tragedies are highly publicised, particularly when high-profile athletes are involved. To date, limited evidence for the efficacy of cardiovascular pre-participation screening exists outside of the Italian experience. Furthermore, limited data exists examining the impact of ethnicity on cardiac adaptations to physical training. Whilst the cardiovascular benefits of exercise are well known, the impact of life-long endurance exercise is less well understood. Long term high-intensity endurance exercise is associated with changes in cardiac morphology together with electrocardiographic alterations that are believed to be physiologic in nature. Recent data however, has suggested a number of deleterious adaptive changes in cardiac structure, function and electrical activity in response to life-long endurance activity. Aims and Objectives - The aims of this PhD were; 1) To find an effective preparticipation screening method that would successfully identify pre-existing cardiovascular abnormalities, 2) To identify the prevalence of hypertrophic cardiomyopathy and Long QT syndrome in elite UK athletes; 3) To examine the impact and significance of ethnicity upon left ventricular remodelling in elite athletes, and 4) To examine the acute and chronic impact of ultra-endurance exercise across the life-span in male endurance athletes. Major Results and Conclusions – 1) Study 2 sought to confirm the efficacy of resting 12-Lead ECG ‘alongside’ personal/family history questionnaires and physical examinations as collective tools to identify diseases that have the potential of causing sudden death within a cohort of elite junior athletes (n=1074) and physically active school children (n=1646). Nine participants were identified with a positive diagnosis of a disease associated with SCD. None of those diagnosed with a disease associated with SCD were symptomatic or had a family history of note. Thus, personal symptoms and family history questionnaires alone are inadequate in the identification of individuals with diseases associated with SCD. In conclusion, resting 12-Lead ECG is paramount when screening for diseases that have the potential of causing sudden death in the young. 2) Study 3 examined 3,500 asymptomatic elite athletes (75% male) with a mean age of 20.5 ± 5.8 years with 12-lead ECG and 2-dimensional echocardiography. None had a known family history of HCM. Of the 3,500 athletes, 53 (1.5%) had LVH (mean 13.6 ± 0.9mm, range 13 to 16mm), and of these 50 had a dilated LV cavity with normal diastolic function to indicate physiological left ventricular hypertrophy. Three (0.08%) athletes with LVH had a non-dilated LV cavity and associated deep T-wave inversion that could have been consistent with HCM. However, none of the 3 athletes had any other phenotypic features of HCM on further non-invasive testing and none had first-degree relatives with features of HCM. In conclusion, the prevalence of HCM in elite athletes is significantly less than in the general population; with the demands of strenuous exercise on the cardiovascular system selecting out most individuals with HCM. Study 4 examined 2000 elite athletes in order to identify the prevalence of Long QT syndrome. Three athletes had a QTc value of >500 ms and all exhibited one of: paradoxical prolongation of QTc during exercise, a confirmatory genetic mutation, or prolonged QTc in a first-degree relative. In contrast, none of the athletes with a QTc value of <500 ms had any other features to indicate LQTS. Accordingly, the prevalence of a prolonged QTc interval in elite British athletes is 0.4%. 3) Study 6 examined 300 nationally ranked UK black male athletes (mean age 20.5 years) in comparison to 150 black and white sedentary individuals and 300 highly-trained white male athletes. Black athletes exhibited greater LV wall thickness and cavity size compared with sedentary black and white individuals. Black athletes had greater LV wall thickness compared with white athletes. A minority of black athlete’s exhibit LVH ≥15 mm; proposing that in the absence of cardiac symptoms or a family history of HCM, an LV wall thickness ≥15 mm in black athletes may represent physiologic LVH when the LV cavity is enlarged and diastolic indexes are normal. 7 black athletes (12%) with LVH displaying deep T-wave inversions in leads V1 to V4. In conclusion, in the absence of obvious pathology, these electrical anomalies in black athletes likely represent a normal spectrum of ECG changes in response to physical training. 4) Study 8 examined 17 male participants (age 33.5 ± 6.5 years, 26–40 years) using cardiac magnetic resonance (CMR) and echocardiography before and after a marathon to investigate the relationship between systolic function and diastolic function against biomarkers of cardiac damage. Results demonstrates biomarkers of myocardial cell damage following an acute bout of prolonged exercise are not associated with either systolic or diastolic functional measures, and do not seem to be associated with any detectable myocardial inflammation, oedema, or scarring using either gold standard techniques of gadolinium enhanced CMR or echocardiography respectively. The impact of multiple episodes of prolonged exercise, as experienced by highly trained veteran endurance athlete is not fully understood. 5) Study 10 examined the cardiac structure and function of 12 life-long, competitive endurance veteran athletes (> 50 yrs, mean ± SD marathons 178 ± 209 (range 20 – 650)) against 17 young male endurance athletes (<40 yrs) using echocardiography and CMR with late gadolinium enhancement (LGE) to assess myocardial fibrosis. Lifelong veteran athletes had smaller LV and RV end-diastolic and end-systolic volumes (p<0.05) but maintained LV and RV systolic function compared with young athletes. In 6 (50%) of the veteran athletes LGE of CMR indicated the presence of myocardial fibrosis; no LGE in the young athletes. The prevalence of LGE in veteran athletes was not associated with the number of competitive marathons or ultra-endurance marathons (>50 miles) completed, age, LV and RV end-diastolic volumes or LV mass (p>0.05). In conclusion, there is limited evidence at present demonstrating that cardiovascular re-modelling following lifelong endurance exercise leads to long-term disease progression, cardiovascular disability or SCD.
|
30 |
Implication deTRPM4 dans des troubles du rythme cardiaque / TRPM4 involved in heart rhythm disordersLiu, Hui 22 May 2013 (has links)
En utilisant la méthode de génétique inverse, la mutation causale d'un bloc de conduction cardiaque familial a été localisée sur le bras long du chromosome 19 en 13.3 dans une grande famille libanaise. Après avoir testé 12 gènes candidats, nous avons trouvé 3 mutations différentes dans trois familles indépendantes de bloc de conduction cardiaque isolé. Les conséquences des 3 mutations ont été explorées par des études électrophysiologiques. Il s'agit dans les 3 cas d'un gain de fonction. Puis, une cohorte de 248 patients atteints de syndrome de Brugada a été étudiée. Onze mutations du gène TRPM4 ont été trouvées chez 20 patients. Les conséquences électrophysiologiques des mutations étaient diverses. Ensuite, des cohortes de patients atteints de syndrome du QT long, de fibrillation auriculaire ou de cardiomyopathie dilaté ont été étudiées. Nous avons également trouvé des mutations ou des variants prédisposants du gène TRPM4 chez ces patients. Une étude électrophysiologique doit être réalisée pour comprendre le rôle de TRPM4 dans ces autres pathologies. Enfin, notre étude immunohistochimique a démontré que TRPM4 est fortement exprimé dans le système de conduction cardiaque mais aussi plus faiblement dans les cardiomyocytes auriculaires et ventriculaires communs. Ce travail a permis d'impliquer pour la première fois le gène TRPM4 dans des maladies humaines. Ce travail donne les bases pour comprendre le rôle du canal TRPM4 dans le fonctionnement cardiaque. C'est le préalable nécessaire avant de pouvoir développer de nouvelles thérapeutiques dans le futur / By using reverse genetics, the causal mutation of a familial cardiac conduction block was localized to the long arm of chromosome 19 in 13.3. After screening 12 candidate genes, we found 3 different mutations in three independent families with isolated cardiac conduction block. The consequences of these 3 mutations were explored by electrophysiological studies. In all 3 mutations it was a gain of function. Then, a cohort of 248 patients with a Brugada syndrome was studied. Eleven mutations were found in the TRPM4 gene in 20 patients. The electrophysiological consequences of these mutations were diverse. Then, cohorts of patients with long QT syndrome, atrial fibrillation, and dilated cardiomyopathy were studied. We found also mutations or predisposing variants in these patients. An electrophysiology study should be conducted to understand the role of TRPM4 in these other pathologies. Finally, our immunohistochemical study showed that TRPM4 is highly expressed in the cardiac conduction system but also although with less intensity in common auricular and ventricular cardiomyocytes. This work implied for the first time the TRPM4 gene in human diseases. This work provides the basis to understand the role of the TRPM4 channel in cardiac function. This is a prerequisite to be able to develop novel therapies in the future
|
Page generated in 0.1724 seconds